ChemoCentryx drug meets main goal in mid-stage study

(Reuters) - ChemoCentryx Inc said its experimental drug was as effective as standard of care in treating patients with a rare type of autoimmune disease in a mid-stage study, sending its shares up 11.3 percent in light premarket trading.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro